Pharmaceutical company that originally developed the drug asset now owned by Spruce Biosciences.
Investment Insights
AI-generated insights about BioMarin Pharmaceutical Inc. from various financial sources
Wednesday, October 8, 2025
Viewed as a case study of poor corporate strategy for selling off a valuable asset (now owned by SPRB) to pursue a different drug that ultimately failed. This serves as a cautionary tale about management decisions.
Monday, October 6, 2025
Mentioned as the company that sold a valuable asset to Spruce Biosciences (SPRB), a practice they are known for with assets deemed too small for their portfolio.
Wednesday, October 8, 2025
Viewed as a case study of poor corporate strategy for selling off a valuable asset (now owned by SPRB) to pursue a different drug that ultimately failed. This serves as a cautionary tale about management decisions.
Monday, October 6, 2025
Mentioned as the company that sold a valuable asset to Spruce Biosciences (SPRB), a practice they are known for with assets deemed too small for their portfolio.